78.19 -2.43 (-3.00%)
DNA
Stock Details
Last Trade:78.19 Change:-2.43 (-3.00%) Prev Close:80.62 Open: 81.01 Days Range:78.19 – 83.05 52 Week Range: 0.01 - 999.99 Volume:6303931 P/E: 27.15EPS:2.88
View AllRecent Alerts 10/07/08
Recent Alert on 10/07/08 at 7:44am
Genentech (DNA) and Biogen (BIIB) Announce Phase III Study of Rituxan(R) Met Primary Endpoint
Genentech (DNA) and Biogen (BIIB) Announce Phase III Study of Rituxan(R) Met Primary Endpoint
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) today announced that a global Phase III study of Rituxan(R) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival,... Read More
Recent Alert on 10/06/08 at 9:30am
Morning Movers 10/06: Citigroup (C) Lower on Wachovia Battle; Imclone (IMCL) Up After Eli Lilly Takeover
Morning Movers 10/06: Citigroup (C) Lower on Wachovia Battle; Imclone (IMCL) Up After Eli Lilly Takeover
Recent Alert on 10/06/08 at 9:14am
Genentech and OSI Phama Said Avastin/Tarceva Combo Fails As Second-Line Treatment For Lung Cancer
Genentech and OSI Phama Said Avastin/Tarceva Combo Fails As Second-Line Treatment For Lung Cancer
Recent Alert on 09/09/08 at 7:30am
Genentech (DNA) volatility Flat; shares trading above Roche $89 offer
Genentech (DNA) volatility Flat; shares trading above Roche $89 offer
View AllRecent Press Releases
Press Release on 10/07/08 at 1:30am
Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
Press Release on 10/06/08 at 1:30am
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
Press Release on 10/03/08 at 10:20am
Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: DISH, DNA, RT, LEA, IRM, ERES
Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: DISH, DNA, RT, LEA, IRM, ERES
Press Release on 10/03/08 at 1:30am
Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy
Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 10/02/08 at 8:16am
Top Pre-Market Analyst Upgrades (AMGN, CPLP, DRIV, DSX, DNA, GNK, MAKO)
Top Pre-Market Analyst Upgrades (AMGN, CPLP, DRIV, DSX, DNA, GNK, MAKO)